Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Investing Activities data on file, last reported at $192.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 17.28% year-over-year to $192.2 million in Q1 2026; TTM through Mar 2026 was $60.6 million, a 129.07% increase from a year earlier, with the FY2025 full-year figure at $32.3 million, up 111.78% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $192.2 million, up from $27.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for MDGL reached as high as $192.2 million in Q1 2026 and fell as low as -$362.1 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$20.3 million across 5 years, with a median of $27.6 million in 2025.
• Across the five-year window, Cash from Investing Activities jumped 324.39% in 2022 and slumped 3171.65% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $66.4 million in 2022, then sank by 645.47% to -$362.1 million in 2023, then jumped by 86.76% to -$47.9 million in 2024, then surged by 157.52% to $27.6 million in 2025, then jumped by 596.85% to $192.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $192.2 million in Q1 2026, $27.6 million in Q4 2025, and -$207.0 million in Q3 2025.